Focus research 2022 SIGNATHER team

Development of a technique to identify RHO GTPase inhibitors

The SIGNATHER team has developed a new technique based on the coupling of phage display and green fluorescent protein fractionation (split-GPF) to identify intracellular antibodies capable of inhibiting RHO GTPase signaling. The team has used this technique to identify an intracellular antibody called RH28, which is capable of selectively inhibiting certain RHOs and their associated phenotypes in melanoma cells. This work paves the way for future therapeutic strategies based on the disruption of protein-protein interactions using intracellular antibodies. To find out more

To find out more about the IUCT-Oncopole and CRCT-Oncopole research focuses, please click here